Zydus Lifesciences Ltd
ZYDUSLIFEZydus Lifesciences Ltd
ZYDUSLIFEPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
28.02 | 5.49 | 0.28% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
43.14 | 6.21 | 0.54% |
Forecast & Ratings
Detailed Forecastfrom 28 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 9,542.40 | 9,504.90 | 12,018.10 | 13,366.70 | 14,367.00 | 14,449.10 | 17,693.00 | 17,424.00 | 19,854.50 | 19,856.50 | ||||||||||
Raw Materials | 3,107.00 | 3,557.70 | 4,437.40 | 4,826.10 | 5,013.80 | 4,958.30 | 5,907.50 | 6,072.00 | 14,177.30 | 14,179.30 | ||||||||||
Power & Fuel Cost | 168.80 | 174.50 | 226.30 | 247.20 | 268.80 | 246.90 | 315.00 | 361.60 | ||||||||||||
Employee Cost | 1,263.70 | 1,485.20 | 1,854.50 | 2,124.10 | 2,395.80 | 2,295.10 | 2,434.10 | 2,765.60 | ||||||||||||
Selling & Administrative Expenses | 1,824.10 | 1,648.60 | 1,944.70 | 1,970.30 | 2,384.80 | 2,237.40 | 2,210.60 | 2,697.90 | ||||||||||||
Operating & Other expenses | 735.20 | 609.10 | 613.30 | 1,024.80 | 1,770.10 | 1,551.80 | 902.00 | 2,089.20 | ||||||||||||
EBITDA | 2,443.60 | 2,029.80 | 2,941.90 | 3,174.20 | 2,533.70 | 3,159.60 | 5,923.80 | 3,437.70 | 5,677.20 | 5,677.20 | ||||||||||
Depreciation/Amortization | 292.10 | 373.30 | 538.80 | 598.60 | 696.50 | 669.60 | 713.00 | 722.70 | 764.10 | 764.10 | ||||||||||
PBIT | 2,151.50 | 1,656.50 | 2,403.10 | 2,575.60 | 1,837.20 | 2,490.00 | 5,210.80 | 2,715.00 | 4,913.10 | 4,913.10 | ||||||||||
Interest & Other Items | 52.80 | 44.60 | 91.10 | 193.50 | 341.80 | 158.80 | 127.00 | 129.90 | 81.20 | 81.20 | ||||||||||
PBT | 2,098.70 | 1,611.90 | 2,312.00 | 2,382.10 | 1,495.40 | 2,331.20 | 5,083.80 | 2,585.10 | 4,831.90 | 4,831.90 | ||||||||||
Taxes & Other Items | 164.80 | 124.20 | 536.20 | 533.30 | 318.80 | 197.60 | 596.50 | 624.80 | 972.40 | 972.40 | ||||||||||
Net Income | 1,933.90 | 1,487.70 | 1,775.80 | 1,848.80 | 1,176.60 | 2,133.60 | 4,487.30 | 1,960.30 | 3,859.50 | 3,859.50 | ||||||||||
EPS | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.26 | 38.14 | 38.13 | ||||||||||
DPS | 3.20 | 3.20 | 3.50 | 3.50 | 3.50 | 3.50 | 2.50 | 6.00 | 3.00 | 6.00 | ||||||||||
Payout ratio | 0.17 | 0.22 | 0.20 | 0.19 | 0.30 | 0.17 | 0.06 | 0.31 | 0.08 | 0.16 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Zydus Lifesciences Ltd | 28.02 | 5.49 | 0.28% |
Sun Pharmaceutical Industries Ltd | 38.18 | 6.16 | 0.89% |
Cipla Ltd | 29.17 | 5.07 | 0.87% |
Dr Reddy's Laboratories Ltd | 19.02 | 4.56 | 0.63% |
Price Comparison
Compare ZYDUSLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Zydus Lifesciences Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Kotak Flexicap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9941% | Percentage of the fund’s portfolio invested in the stock 2.25% | Change in the portfolio weight of the stock over the last 3 months -0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/63 (-2) |
Parag Parikh Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7151% | Percentage of the fund’s portfolio invested in the stock 1.16% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/92 (+1) |
ICICI Prudential Focused Equity Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2586% | Percentage of the fund’s portfolio invested in the stock 3.53% | Change in the portfolio weight of the stock over the last 3 months 0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/41 (+1) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Zydus Lifesciences Ltd
Events
Dividend Trend
No Trend In Dividends
ZYDUSLIFE has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.81 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 26, 2024
Dividend/Share
₹3.00
Ex DateEx Date
Jul 26, 2024
Past Dividends
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹6.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateJul 28, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Jul 28, 2022
Cash Dividend
Ex DateEx DateJul 28, 2021
Dividend/Share
₹3.50
Ex DateEx Date
Jul 28, 2021
Cash Dividend
Ex DateEx DateMar 23, 2020
Dividend/Share
₹3.50
Ex DateEx Date
Mar 23, 2020
Cash Dividend
Ex DateEx DateJul 25, 2019
Dividend/Share
₹3.50
Ex DateEx Date
Jul 25, 2019
News & Opinions
Stocks to watch today — May 11, 2023
1 year ago•The Hindu Businessline
Zydus Life rises on USFDA nod for schizophrenia drug
1 year ago•Business Standard
Zydus Lifesciences’ Rs 750 cr-share buyback open between June 23-July 6
2 years ago•Business Standard
News Video
Sharvil Patel Discusses Zydus Lifesciences Rebranding & Biz Outlook | The Medicine Box | CNBC-TV18
2 years ago•CNBC-TV18
Domestic branded generic formulations market can grow at 10-12%: Industry
2 years ago•Business Standard
Zydus Lifesciences jumps over 5% after US arm buys global rights for BridgeBio’s Nulibry
2 years ago•Moneycontrol
Zydus Gets DCGI Nod for Drug to Treat Anaemia Associated with Chronic Kidney Disease
2 years ago•News18
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.23%, vs industry avg of 9%
Decreasing Market Share
Over the last 5 years, market share decreased from 6.03% to 5.5%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 15.86%, vs industry avg of 15.09%